灯盏乙素-PEG-PLGA载药纳米粒的制备及质量评价

发布时间：2018-06-13 14:29

  本文选题：灯盏乙素 + 聚乙二醇-聚乳酸/羟基乙酸共聚物　； 参考：《中国药房》2015年19期

【摘要】：目的:制备灯盏乙素-聚乙二醇-聚乳酸/羟基乙酸共聚物(PEG-PLGA)载药纳米粒,优化其处方,并进行质量评价。方法:采用复乳-溶剂蒸发法制备灯盏乙素-PEG-PLGA载药纳米粒。以包封率为评价指标,以初乳与外水相的比例、灯盏乙素和PEG-PLGA质量浓度为因素,通过单因素试验和正交试验优化处方;测定最优处方所制纳米粒的表观形态、粒径、Zeta电位、载药量、包封率和稳定性。结果:最优处方为初乳与外水相的比例1∶15,灯盏乙素质量浓度10 mg/ml,PEG-PLGA质量浓度15 mg/ml。所制得纳米粒为圆形或椭圆形,平均粒径为(78.54±2.21)nm,Zeta电位为(-23.07±1.39)m V,载药量为(1.67±0.12)%,包封率为(45.32±1.29)%;纳米粒在4℃下保存3个月内粒径和包封率无明显变化。结论:成功制得具有较好理化性质和稳定性的灯盏乙素-PEG-PLGA纳米粒。
[Abstract]:Aim: to prepare breviscapine-poly (ethylene glycol)-poly (lactic acid) / glycolic acid copolymers (PEG-PLGA) loaded nanoparticles, optimize their formulation and evaluate their quality. Methods: breviscapine-PEG-PLGA nanoparticles were prepared by double emulsion-solvent evaporation method. The encapsulation efficiency was used as the evaluation index, the ratio of colostrum to outer water, the mass concentration of breviscapine and PEG-PLGA as the factors, the formulation was optimized by single factor test and orthogonal test, the apparent morphology of the nanoparticles prepared by the optimal formulation was determined, and the particle size was determined by Zeta potential. Drug loading, encapsulation efficiency and stability. Results: the optimal formulation was 1: 15 for colostrum and 1: 15 for external water. The mass concentration of breviscapine was 10 mg / ml PEG-PLGA and 15 mg / ml. The average particle size was 78.54 卤2.21nmGV, the average particle size was -23.07 卤1.39mV, the drug loading was 1.67 卤0.12mV, the entrapment efficiency was 45.32 卤1.290.The particle size and entrapment efficiency had no significant change within 3 months after preservation at 4 鈩，

本文编号：2014330